Table 1.
Characteristics of included trials
| Study ID | Sample size (EG/CG) | Age(years, mean) | Sex (male/female) | Experimental group | Comparison group | Duration of treatment | Outcome assessment |
|---|---|---|---|---|---|---|---|
| Wu et al25 | 58 (30/28) | EG: 68.65±7.07 CG: 67.91±7.37 |
NR | EXD (a dose/d, Qd, oral administration) | Caltrate tablets (600 mg, Qd, oral administration) | 6 months | BMD (LS, FGT Ca, P, ALP |
| Zhu and Gu26 | 70 (35/35) | EG: 61.2±5.6 CG: 60.4±5.8 |
Postmenopausal women | EXD (a dose/d, Bid, oral administration) + CG | Salmon Calcitonin (50 IU every day, intramuscular injection) | 3 months | BMD (LS ALP, BGP, CT, E2 |
| Gao27 | 78 (39/39) | EG: 42.3±5.6 CG: 40.7±4.9 |
EG: 19/20 CG: 21/18 |
EXD (a dose/d, oral administration) | Women: Nilestriol (2~4 mg every 2 weeks, oral administration) Men: testosterone propionate (20~25 mg every 2 weeks, intramuscular) |
2 months | BMD (LS, FN, WA, FGT |
| Liu28 | 138 (69/69) | 56.2±9.3 | Postmenopausal women | Modified EXD (a dose/d, oral administration) + CG | Caltrate tablets (600 mg, Qd, oral administration) and calcitriol (0.25 μg, Qd, oral administration) | 3 months | BMD (LS, FN Ca, P, ALP, ADR |
| Jiang et al29 | 70 (35/35) | EG: 64.64±8.73 CG: 69.41±5.21 |
Postmenopausal women | Modified EXD (a dose/d, oral administration) + CG | Caltrate tablets (600 mg, Qd, oral administration) and calcitriol (0.25 μg, Bid, oral administration) | 3 months | BMD (LS, FN Ca, P, ALP, ADR |
| Liu30 | 70 (35/35) | EG: 42.5±5.1 CG: 43.6±5.4 |
EG: 15/20 CG: 16/19 |
Modified EXD (a dose/d, Bid, oral administration) | Caltrate tablets (600 mg, Qd, oral administration) | 2 months | BMD (LS, FN, WA, FGT VAS score Ca, P, ALP |
| Xu et al31 | 80 (40/40) | EG: 63.19±5.13 CG: 64.32±6.34 |
Postmenopausal women | Modified EXD (a dose/d, oral administration) + CG | Caltrate tablets (600 mg, Qd, oral administration), Vitamin D (125 IU, Qd, oral administration) and Alfacalcidol (0.25 μg, Qd, oral administration) | 3 months | BMD (FN ALP, E2 |
| Ye et al32 | 80 (40/40) | EG: 48.40±7.58 CG: 47.10±3.11 |
Postmenopausal women | EXD (a dose/d, Bid, oral administration) + CG | Elcatonin (10 IU per time, twice a week, intramuscular injection) | 3 months | BMD (LS, tibia VAS score, ADR |
Abbreviations: EG, experimental group; CG, comparison group; NR, not reported; EXD, Erxian decoction; LS, lumbar spine; FN, femoral neck; WA, Ward’s area; FGT, femoral great trochanter; BMD, bone mineral density; Ca, calcium; P, phosphorus; CT, calcitonin; E2, estradiol; ADR, adverse drug reaction; VAS, visual analog scale; ALP, alkaline phosphatase; BGP, bone gla protein.